Forschung & Innovation
Publikationen
Philanthropic drug development
PMU Autor*in
Eva M. Murauer
Alle Autor*innen
Marc Reichel, Eva M. Murauer, Martin Steiner, Christoph Coch, Hubert Truebel
Fachzeitschrift
DRUG DISCOVERY TODAY
Kurzfassung
Philanthropic drug development (PDD) addresses gaps in traditional pharmaceutical innovation, particularly for rare and underserved diseases. Cost and timeline challenges discourage new investments, especially in niche therapeutic areas. Patient organizations (POs) are uniquely positioned to help to reduce development challenges by providing expertise, supporting early research, fostering collaborations, and driving patient-centered clinical trials. PDD relies on effective partnerships between POs, pharmaceutical companies, and other stakeholders, ensuring that patient perspectives inform the drug development process. PDD is poised to relieve the pressure on the traditional drug development process and thereby foster beneficial patient-focused innovations. In doing so, PDD allows pharmaceutical companies to expand their drug development activities into commercially unrewarding {} areas, diversifying their portfolios beyond competitive fields.
Keywords
RARE DISEASES, Drug development, Patient engagement, Patient organizations, Philanthropy